EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ceftolozane-tazobactam and ceftazidime-avibactam efficacy against K. pneumoniae: first NDM-5 and OXA-232 report from Türkiye

Belgin Altun, Gülşen Hazırolan, Deniz Gür

The Journal of Infection in Developing Countries · 2026

DOI: 10.3855/jidc.21385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2026. Verfasst von Belgin Altun und 2 weiteren Autor:innen. Beteiligte Einrichtung: Vocational School of Health Services, Hacettepe University, Ankara, Turkey. Hauptthemen laut MEDLINE: Azabicyclo Compounds, Ceftazidime, Tazobactam, Anti-Bacterial Agents. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Ceftolozane-tazobactam (CLZ-TAZ) and ceftazidime-avibactam (CAZ-AVB) are recently developed β-lactam/β-lactamase inhibitor combinations active against resistant Gram-negative bacteria. This study compared the in vitro activities of ceftazidime, meropenem, piperacillin-tazobactam (PIP-TAZ), CLZ-TAZ, and CAZ-AVB in Klebsiella pneumoniae isolates from Hacettepe University hospitals and investigated the carbapenemase types detected over the past five years. Methodology: A total of 550 K. pneumoniae isolates were collected consecutively from invasive clinical samples between 2015 and 2022 according to the SENTRY protocol. Identification was performed using matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS). Susceptibility testing for ceftazidime, meropenem, PIP-TAZ, CLZ-TAZ, and CAZ-AVB was carried out by broth microdilution and interpreted according to EUCAST standards. Carbapenemase genes were determined by whole-genome sequencing.

Results

Isolates were obtained from blood (n = 191), skin/soft tissue (n = 130), urine (n = 102), respiratory (n = 86), and intra-abdominal (n = 41) samples. Resistance rates were 62.3% for ceftazidime, 29.7% for meropenem, 60.4% for PIP-TAZ, 43.1% for CLZ-TAZ, and 8.7% for CAZ-AVB. The predominant carbapenemases were OXA-48, OXA-232, NDM-1, OXA-181, and KPC-2. Multiple carbapenemases coexisted in 10% of carbapenem-resistant isolates.

Conclusions

CAZ-AVB demonstrated superior activity compared to CLZ-TAZ in this high-resistance setting, While OXA-48 and NDM-1 remain the most frequent carbapenemases, emerging enzymes including OXA-181, OXA-232, KPC-3, and NDM-5 were also detected. The coexistence of multiple enzymes in single isolates highlights a growing therapeutic challenge, emphasizing the need for continued surveillance and effective antimicrobial stewardship.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Azabicyclo CompoundsCeftazidimeTazobactamAnti-Bacterial AgentsKlebsiella pneumoniaeCephalosporinsKlebsiella Infectionsbeta-Lactamase InhibitorsHumansMicrobial Sensitivity TestsDrug Combinationsbeta-LactamasesThird Generation CephalosporinsTurkeyBacterial Proteins

Stichwörter der Autor:innen

K. pneumoniaeNDM-5OXA-232carbapenem-resistanceceftazidime-avibactamceftolozan-tazobactam

Substanzen

Azabicyclo CompoundsCeftazidimeTazobactamavibactam, ceftazidime drug combinationDrug CombinationsAnti-Bacterial Agentsbeta-LactamasesThird Generation Cephalosporinsceftolozane, tazobactam drug combinationCephalosporins

Autor:innen und Institutionen

  • Vocational School of Health Services, Hacettepe University, Ankara, Turkey.
  • Department of Medical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.

Zitieren

APA

Altun, B., Hazırolan, G., & Gür, D. (2026). Ceftolozane-tazobactam and ceftazidime-avibactam efficacy against K. pneumoniae: first NDM-5 and OXA-232 report from Türkiye. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.21385

Vancouver

Altun B, Hazırolan G, Gür D. Ceftolozane-tazobactam and ceftazidime-avibactam efficacy against K. pneumoniae: first NDM-5 and OXA-232 report from Türkiye. The Journal of Infection in Developing Countries. 2026. doi:10.3855/jidc.21385

BibTeX
@article{Altun2026,
  author = {Altun, Belgin and Hazırolan, Gülşen and Gür, Deniz},
  title = {Ceftolozane-tazobactam and ceftazidime-avibactam efficacy against K. pneumoniae: first NDM-5 and OXA-232 report from Türkiye},
  journal = {The Journal of Infection in Developing Countries},
  year = {2026},
  doi = {10.3855/jidc.21385}
}
Kostenlos starten →